Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Natalie Callander
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07479979CT.gov Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07569757CT.gov Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07200102CT.gov Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | — | Recruiting | — | — | — |
NCT07579234CT.gov A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07514052CT.gov Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study | — | Recruiting | — | — | — |
NCT07138209CT.gov A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06822972CT.gov HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM | — | Recruiting | — | — | — |
NCT06744894CT.gov SIL as Maintenance Therapy in Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT06452446CT.gov Telehealth-based Symptom Management for Veterans Treated With Selinexor | — | Active Not Recruiting | — | — | — |
NCT06225310CT.gov A Trial of Selinexor, Ruxolitinib and Methylprednisolone | — | Recruiting | — | — | — |
Show 40 more trialsShow fewer
NCT06169215CT.gov Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06158841CT.gov Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05820763CT.gov Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | — | Withdrawn | — | — | — |
NCT05954780CT.gov Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05530421CT.gov Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05675319CT.gov Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy | — | Terminated | — | — | — |
NCT04756401CT.gov Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05478993CT.gov Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement | — | Unknown | — | — | — |
NCT05422027CT.gov Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05900882CT.gov SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | — | Recruiting | — | — | — |
NCT05170789CT.gov Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT05028348CT.gov A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04941937CT.gov Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM | — | Unknown | — | — | — |
NCT05201118CT.gov A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma | — | Unknown | — | — | — |
NCT04843579CT.gov Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT04925193CT.gov Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04782687CT.gov Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04717700CT.gov Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | — | Active Not Recruiting | — | — | — |
NCT04939142CT.gov A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT04891744CT.gov Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | — | Unknown | — | — | — |
NCT04877275CT.gov ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | — | Unknown | — | — | — |
NCT04764942CT.gov Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | — | Active Not Recruiting | — | — | — |
NCT04661137CT.gov A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | — | Suspended | — | — | — |
NCT04640779CT.gov Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04519476CT.gov Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | — | Unknown | — | — | — |
NCT04414475CT.gov A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | — | Recruiting | — | — | — |
NCT03732703CT.gov Myeloma-Developing Regimens Using Genomics (MyDRUG) | — | Completed | — | — | — |
NCT06212596CT.gov Selinexor, Cyclophosphamide and Prednisone in Myeloma | — | Completed | — | — | — |
NCT03589222CT.gov SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02780609CT.gov Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | — | Completed | — | — | — |
NCT03110562CT.gov Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02831686CT.gov A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | — | Completed | — | — | — |
NCT02628704CT.gov Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | — | Withdrawn | — | — | — |
NCT02343042CT.gov Selinexor and Backbone Treatments of Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT02389543CT.gov Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | — | Withdrawn | — | — | — |
NCT02336815CT.gov Selinexor Treatment of Refractory Myeloma | — | Completed | — | — | — |
NCT02186834CT.gov Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02199665CT.gov Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT07215832CT.gov Karyopharm Expanded Access Program for Selinexor | — | Available | — | — | — |
NCT03850704CT.gov Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Selinexor (this asset) | Natalie Callander | P3 | B · 60 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Selinexor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 72 |
| Mantle Cell Lymphoma | — | P4 | BB · 70 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Selinexor in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/selinexor-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →